Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- DSP Obtains Approval for Antipsychotic Drug Latuda in Canada
June 19, 2012
- Pfizer Japan Top Choice in All Factors Doctors Consider Important When Prescribing Generics: QLife Survey
June 19, 2012
- Takeda to Cease Distribution of 13 former Wyeth Products, Except for Prevenar, BeneFIX, Enbrel
June 19, 2012
- [Data] Sales of Takeda’s Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Otsuka HD's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Astellas's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Daiichi Sankyo's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Eisai's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Mitsubishi Tanabe's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Dainippon Sumitomo's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Taisho HD's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Shionogi's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Ono's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Santen's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Kyorin HD's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Kaken's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Mochida's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Nippon Shinyaku's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Kissei's Mainstay Products in FY2011
June 19, 2012
- [Data] Sales of Zeria's Mainstay Products in FY2011
June 19, 2012
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…